Improved survival with vemurafenib in melanoma with BRAF V600E mutation (Q24631953)

From Wikidata

Jump to navigation Jump to search

scientific article

• Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

edit

Language	Label	Description	Also known as
English	Improved survival with vemurafenib in melanoma with BRAF V600E mutation	scientific article	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Statements

instance of

scholarly article

1 reference

stated in

PubMed

PubMed publication ID

21639808

retrieved

13 November 2016

title

Improved survival with vemurafenib in melanoma with BRAF V600E mutation (English)

1 reference

stated in

PubMed

PubMed publication ID

21639808

retrieved

13 November 2016

main subject

vemurafenib

0 references

melanoma

0 references

author

Dirk Schadendorf

series ordinal

15

0 references

Antoni Ribas

series ordinal

16

0 references

Paul Lorigan

series ordinal

12

0 references

Claus Garbe

series ordinal

8

0 references

Axel Hauschild

series ordinal

2

0 references

Reinhard Dummer

series ordinal

7

0 references

Michele Maio

series ordinal

10

0 references

Alexander M. M. Eggermont

series ordinal

20

object named as

Alexander M M Eggermont

0 references

Caroline Robert

series ordinal

3

object named as

Caroline Robert

0 references

Grant McArthur

object named as

Grant A McArthur

series ordinal

28

0 references

Keith Flaherty

series ordinal

27

object named as

Keith T Flaherty

0 references

Paolo Antonio Ascierto

series ordinal

5

object named as

Paolo Ascierto

0 references

James Larkin

series ordinal

6

object named as

James Larkin

0 references

John B A G Haanen

series ordinal

4

object named as

John B Haanen

0 references

David Hogg

series ordinal

11

object named as

David Hogg

0 references

Alessandro Testori

series ordinal

9

object named as

Alessandro Testori

0 references

Jeffrey A Sosman

series ordinal

18

object named as

Jeffrey A Sosman

0 references

Celeste Lebbe

series ordinal

13

object named as

Celeste Lebbe

0 references

Thomas Jouary

series ordinal

14

object named as

Thomas Jouary

0 references

Keith Nolop

series ordinal

22

object named as

Keith Nolop

0 references

author name string

Paul B Chapman

series ordinal

1

0 references

Steven J O'Day

series ordinal

17

0 references

John M Kirkwood

series ordinal

19

0 references

Brigitte Dreno

series ordinal

21

0 references

Jiang Li

series ordinal

23

0 references

Betty Nelson

series ordinal

24

0 references

Jeannie Hou

series ordinal

25

0 references

Richard J Lee

series ordinal

26

0 references

language of work or name

English

0 references

publication date

30 June 2011

0 references

published in

The New England Journal of Medicine

0 references

volume

364

0 references

issue

26

0 references

page(s)

2507-16

0 references

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

7 April 2017

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

7 April 2017

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

7 April 2017

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

7 April 2017

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

7 April 2017

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

7 April 2017

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

7 April 2017

Cancer statistics, 2010

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

7 April 2017

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

7 April 2017

Mutations of the BRAF gene in human cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

7 April 2017

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

7 April 2017

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

7 April 2017

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

7 April 2017

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

7 April 2017

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

7 April 2017

Final version of 2009 AJCC melanoma staging and classification

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

7 April 2017

Distinct sets of genetic alterations in melanoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

7 April 2017

Sorafenib-induced premalignant and malignant skin lesions

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

27 September 2017

Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

27 September 2017

The histologic spectrum of epithelial neoplasms induced by sorafenib

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

27 September 2017

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

27 September 2017

Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

27 September 2017

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

28 November 2018

BRAF mutations in metastatic melanoma: a possible association with clinical outcome.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549296

retrieved

28 November 2018

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21639808

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1056/NEJMOA1103782

1 reference

stated in

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

144205

OpenCitations bibliographic resource ID

144205

1 reference

stated in

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

144205

PMC publication ID

3549296

1 reference

stated in

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

144205

PubMed publication ID

21639808

1 reference

stated in

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

144205

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24631953&oldid=2119038851"